- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4: Making Cost-Based Treatment Decisions
Harvoni has shown results within the first 8 weeks of treatment, which would save costs, Matthew D. Harman, PharmD, MPH, does not think many patients or providers will be making cost-based hepatitis C treatment decisions.
Harvoni has shown results within the first 8 weeks of treatment, which would save costs, Matthew D. Harman, PharmD, MPH, does not think many patients or providers will be making cost-based hepatitis C treatment decisions. Typically, less than 30% of providers are actually aware of medication costs, he said.
Express Scripts calculated the cost across the 8-, 12-, and 24-week regimens and found that even with the best rate for Harvoni, the cost of treatment is still in favor of Viekira Pak by about $10,000 per treatment, which benefits plan sponsors struggling to make ends meet.
“Plans sponsors have to choose what’s right for them,” he said.
From MSSP ACOs to Employer Value: Translating Value-Based Principles to Self-Insured Plans
December 12th 2025Value-based care adoption in employer insurance requires replacing fragmented point solutions with unified, at-risk performance contracts that align vendors, providers, and members around total cost and quality goals.
Read More
From Complexity to Clarity: A Path to Value in Employer Health Plans
December 12th 2025Employers struggle to define value from health care spending amid complexity and misaligned incentives. Achieving measurable outcomes requires transparency, incentive realignment, and gradual, employee-centered change.
Read More
